IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma
IDEAYA Biosciences has released preliminary clinical results from a Phase 2 trial of darovasertib, an oral PKC inhibitor, as a treatment for neoadjuvant uveal melanoma. The study, involving 15 patients, demonstrated a 67% eye preservation rate in patients initially planned for enucleation.
Median tumor shrinkage was approximately 39% after six months. Darovasertib was well tolerated, with no serious drug-related adverse events reported. The full data will be presented at the ASCO 2024 Annual Meeting on June 3.
- 67% eye preservation rate (6 of 9 patients) with darovasertib treatment.
- Median tumor shrinkage of ~39% after six months.
- Darovasertib was generally well tolerated, with no serious drug-related adverse events.
- Phase 2 trial results to be presented at the prestigious ASCO 2024 Annual Meeting.
- 13% of patients experienced at least one drug-related Grade 3 adverse event.
- Data on additional patients and further follow-up are still pending.
- The trial only included a small cohort of 15 patients.
Insights
Darovasertib showing a
The drug’s safety profile is also promising. With no serious adverse events and only a small percentage of higher-grade adverse events, it suggests darovasertib is well-tolerated, which is vital for patient compliance and long-term treatment success.
For a retail investor, these positive results could imply potential growth for IDEAYA Biosciences, especially if further data at the ASCO meeting corroborates these findings. However, it’s important to remain cautious. Being in a Phase 2 study, there are still many hurdles before approval and market launch, including potential unforeseen side effects and the results of Phase 3 trials.
IDEAYA’s announcement regarding the Phase 2 trial results for darovasertib in treating uveal melanoma is promising from a market viewpoint. The
From an investment perspective, the positive safety profile—no serious adverse events and limited higher-grade adverse events—suggests there should be fewer regulatory hurdles if the drug proceeds to latter stages. Moreover, presenting this data at the ASCO conference means it gets the visibility it needs among key stakeholders, potentially attracting partnerships or funding.
Investors should keep an eye on the upcoming ASCO presentation for additional data. The stock might experience volatility, usually seen around such presentations. Understanding these dynamics can help in making more informed decisions.
- ~
67% eye preservation rate (6 of 9 enucleation patients) with darovasertib monotherapy neoadjuvant uveal melanoma treatment - Median tumor shrinkage (maximum volume change) of ~
39% after 6 months - Clinical data on additional enucleation patients and with further follow-up from the abstract-summary cut-off date will be presented at ASCO 2024
- Darovasertib was generally well tolerated with no drug-related serious adverse events
- Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024 at 9:51am CDT
Anthony Joshua, MBBS, PhD, FRACP, Head Department of Medical Oncology, Kinghorn Cancer Centre, St. Vincent's Hospital in Sydney, who is the leading principal investigator of the Phase 2 study, will present the clinical data from the Phase 2 Neoadjuvant / Adjuvant trial of Darovasertib in Ocular Melanoma" (NADOM) study. Details of the presentation are as follows:
- Session: Melanoma / Skin Cancers
- Title: A Phase 2 Safety and Efficacy Study of Neoadjuvant/Adjuvant Darovasertib for Localized Ocular Melanoma
- Date: Monday, June 3, 2024, at 9:51 AM CDT
In summary, 15 patients planned for enucleation with localized UM were treated with darovasertib 300mg twice daily. An initial safety cohort of 3 patients were treated for one month, and the remaining 12 patients were treated in an expansion cohort for up to six months as neoadjuvant treatment prior to their primary intervention (enucleation, plaque brachytherapy or external beam radiotherapy (EBRT)) across three Australian centers.
As of the database lock, 11 patients had completed primary treatment, four remained on neoadjuvant treatment, and six patients received adjuvant darovasertib after primary treatment of their UM with three patients completing the planned six months. At that time, approximately
The darovasertib monotherapy neoadjuvant treatment was generally well tolerated. Drug-related adverse events (AEs) were predominantly Grade 1 or Grade 2. Thirteen percent of patients reported at least one drug-related Grade 3 adverse event and no drug-related serious adverse events were observed.
Additional patients and further follow up from the abstract summary cut-off date will be presented on the June 3, 2024, ASCO oral presentation. A copy of the ASCO oral presentation will be available at approximately 10:00am CDT at its Investor Relations portal under "Events" (https://ir.ideayabio.com/) on the day of the presentation.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the content and timing of the ASCO oral presentation. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 20, 2024 and any current and periodic reports filed with the
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-abstract-summary-results-of-asco-2024-oral-presentation-for-phase-2-investigator-sponsored-study-of-darovasertib-in-neoadjuvant-uveal-melanoma-302154551.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
What is IDEAYA Biosciences' recent announcement about?
What is the eye preservation rate reported for darovasertib in the Phase 2 trial?
What is the median tumor shrinkage observed in the darovasertib trial?
Were there any serious adverse events reported for darovasertib?
When and where will the full clinical data of darovasertib be presented?
